WO2004073692A1 - Capsule dure de medicament peu hydrosoluble - Google Patents

Capsule dure de medicament peu hydrosoluble Download PDF

Info

Publication number
WO2004073692A1
WO2004073692A1 PCT/JP2004/001751 JP2004001751W WO2004073692A1 WO 2004073692 A1 WO2004073692 A1 WO 2004073692A1 JP 2004001751 W JP2004001751 W JP 2004001751W WO 2004073692 A1 WO2004073692 A1 WO 2004073692A1
Authority
WO
WIPO (PCT)
Prior art keywords
hard capsule
capsule
water
soluble drug
hard
Prior art date
Application number
PCT/JP2004/001751
Other languages
English (en)
Japanese (ja)
Inventor
Sennichi Kohara
Haengja Kang
Original Assignee
Yamashita, Shinji
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yamashita, Shinji filed Critical Yamashita, Shinji
Priority to JP2005502715A priority Critical patent/JPWO2004073692A1/ja
Publication of WO2004073692A1 publication Critical patent/WO2004073692A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds

Definitions

  • the present invention relates to hard capsules of poorly water-soluble drugs. More specifically, the present invention relates to a medicament for water repellency at a pH in the gastrointestinal tract of 1.2 to 8.0 administered orally.
  • the present invention relates to an eighty-one capsule of a poorly water-soluble drug which not only improves solubility of a soluble drug but also has excellent quality even after long-term storage.
  • Non-Patent Document 1 a drug that is hardly soluble in water is defined as a drug having a solubility of 0.1 mg Zm1 or less.
  • orally administered drugs first dissolve in the gastrointestinal endocrine fluid, migrate to the small intestine, and are absorbed.However, when a poorly water-soluble drug is administered orally, the poorly water-soluble drug is dissolved in the gastrointestinal tract. It is easily analogized and often observed that stool is excreted without being sufficiently absorbed because it does not dissolve in the urine. Many pharmaceutical studies have been made to improve oral solubility by improving the solubility of this poorly water-soluble drug (Non-Patent Document 2).
  • Patent Document 1 A patent has been published that it can be solubilized and a capsule can be prepared, but only the dissolution rate of tablets and PH 7 is compared to improve the solubility of the solubilized formulation of ibuprofen. No comment is made on the solubility at pH 1.2 or 8.0, which is the pH in the digestive tract (Patent Document 1).
  • the poorly water-soluble drug is apparently dissolved in a test tube, but the improvement in oral absorption of the poorly water-soluble drug is not so much different from the above-mentioned treatment method.
  • a drug containing a poorly water-soluble drug precipitates when orally administered and comes into contact with secretory fluid (PH 1.2 to 8.0) in the digestive tract.
  • secretory fluid PH 1.2 to 8.0
  • the essential solubilization method that leads to improvement in oral absorption is that it is also soluble in the gastrointestinal tract. Therefore, recently, a solubilization method that does not precipitate in secretions in the gastrointestinal tract has been reported.
  • Patent Document 2 discloses a drug delivery system containing 10% by weight of poorly water-soluble drugs cyclosporine, difendipine, and indomethacin by the co-solvent effect of a lipid and a surfactant to improve water solubility. It has been published. Although it has been confirmed that these solubilizing formulations do not precipitate when diluted with water, they do not specify oral formulations such as hard capsules that guarantee quality.
  • solubilization by mixing a lipophilic solubilizer such as fats and oils such as medium-chain fatty acid triglyceride and a surfactant have been reported, and for example, oils such as vitamins A, D, and E-cyclosporine can be easily prepared.
  • these drugs have been applied to dissolving drugs, these preparations are basically orally administered and then emulsified in the digestive tract by emulsification, absorbed into the lymph due to the large particles of the emulsion, and then into the body. Sucking Although it is known to be absorbed, the absorption efficiency is poor compared to normal absorption, and oral absorption is often reduced for drugs with strong affinity for fats and oils. Furthermore, few drugs are dissolved by fats and oils alone.
  • Non-Patent Document 4 A gelatin soft capsule (Neoral (registered trademark)) with a small amount and improved oral absorption is on the market (Non-Patent Document 4).
  • amprenavir which is an anti-AIDS agent
  • a) 15% by weight of amprenavir (b) polyethylene glycol and a small amount of propylene glycol as a hydrophilic solubilizer, and (c) a surfactant
  • a soft gelatinous softener containing vitamin E succinate and polyethylene glycol 1000 ester is commercially available.
  • gelatin hard capsules In addition to gelatin soft capsules, gelatin hard capsules have been proposed. For example, a sustained-release hard capsule filled with a semisolid oil-based suspension matrix in which captopril is simply suspended in an oil or fat is commercially available (Non-Patent Document 5). However, this formulation is a sustained-release formulation and is poorly soluble in water. It is not a capsule that improves the solubility of sex drugs.
  • Non-Patent Document 4 WA Ritschel, "Microemulsion technology in the reformulation of cyclosporin; The reason behind the pharmacokinetic properties of Neoral (R)", Clin- Transplant, vol.10, No., p.364-373, 1996
  • soft capsules have a problem that they can be applied only to low-viscosity drug solutions due to the manufacturing method of molding a sheet of molten gelatin into a soft capsule and filling the drug solution at the same time.
  • soft capsules Since the film contains a large amount of plasticizers such as gelatin and glycerin, which are main components, there is also a problem that the film is more susceptible to environmental humidity than hard capsules. For example, if a soft capsule absorbs moisture, it will soften, deform, or stick.
  • hard capsules have been provided with vegetable or synthetic polymer hard capsules instead of gelatin.
  • peripheral equipment such as heating equipment will enable filling of high viscosity chemicals.
  • soft capsules can be manufactured more easily and soft capsules can only produce a liquid solubilizing formulation, but not only liquid but also semi-solid solubilizing formulations can be manufactured.
  • the hard capsule itself is hardly affected by the humidity of the environment, but because of its thin film thickness and greatly affected by the contents to be filled, especially the solubilizing agent, the solubilization is more permissive than the soft gelatin capsule.
  • the type of agent is limited. For example, it is known that even low molecular weight polyethylene dalicol, which is permitted in soft capsules, not only denatures gelatin in hard capsules but also leaks and deforms.
  • the present inventors have searched for a hydrophilic solubilizer capable of solubilizing a poorly water-soluble drug at a high concentration and improved the hydrophilic solubilizer in order to improve oral absorption of a poorly water-soluble drug. Even after filling, we studied hard capsules that do not cause liquid leakage or deformation and maintain quality for a long time. However, it has been found that the quality of the hard capsule is remarkably maintained for a long period of time if a quality preservative for preventing the deterioration of the hard capsule is added to the content of the hard capsule.
  • a hard capsule of a sparingly water-soluble drug characterized in that the content containing the quality preservative is filled in a capsule.
  • the quality preserving agent is (a) purified water, (b) a thickening agent that brings the kinematic viscosity of the content to 100 to 20000 (mp as), and (c) the melting point of the content is 30 to 80 ° C.
  • the quality preservative is (a) purified water, (b) a cellulosic polymer additive or polybierpyrrolidone, or a solution obtained by dissolving and dispersing the above substance in purified water or a polyhydric alcohol or a mixture thereof.
  • the hard capsule according to the above (1) wherein the hard capsule is at least one selected from the group consisting of (c) light caffeic anhydride, (d) a higher fatty alcohol and (e) a glycerin long-chain fatty acid ester.
  • the poorly water-soluble drug used in the present invention is particularly limited as long as the drug has a solubility in water, specifically, water of pH 1.2 to pH 8, which is the pH in the digestive tract, at room temperature of about 0.1 mgZml or less. Not done.
  • the poorly water-soluble drug used in the present invention is not limited to drugs that are prescribed in the Japanese Pharmacopoeia as a drug that hardly dissolves in water, and includes, for example, compounds having biological activity, foods, especially functional foods, herbal medicines, and animals. Drugs, feeds or reagents are included.
  • the poorly water-soluble drugs used in the present invention include, for example, drugs for central nervous system such as phenytoin, imibramine, nitrazepam, haloperidol and salts thereof, and drugs for peripheral nervous system such as indomethacin and fenylbuzone. , Ibuprofen, piroxicam and their salts, and circulating agents such as digoxin, pindolol, difludipine, reserpine, cinnarizine, probucol, clofibrate and their salts, and respiratory agents such as rebifogenin and nos.
  • drugs for central nervous system such as phenytoin, imibramine, nitrazepam, haloperidol and salts thereof
  • drugs for peripheral nervous system such as indomethacin and fenylbuzone.
  • Ibuprofen, piroxicam and their salts and circulating agents such as digoxin, pindolol, difludipine
  • Power pins pranlukast, zosun zolast, montelukast and their salts, etc., digestive tract drugs sofalcone, ursodeoxycholic acid, dongperidone and their salts, and hormonal agents Danazol, Ethinil Estradio , Cortisone acetate, dexamethasone and their salts, urogenital drugs furosemide, spironolactone, tribenoside and their salts, etc., and oncological drugs evening moxifen, busulfan, taxol and their salts, etc.
  • Griseofulvin, ketoconazole, albendazole and their salts such as antibiotics and chemotherapeutic agents, and amprenavir, nelfinavir, ritonavir, sucinavir, and their salts, which are anti-AIDS agents;
  • fat-soluble vitamins such as vitamins A and D or their derivatives, tocopherol acetate, etc., and ticlopidine, amiodorone, oral peramide, ketanserin, verapamil, terfenadine, trifluoroproprazin, and tolodizone.
  • Piodari evening Zon, Ivry flavone, evening Kurori Mus such as cyclosporin and their salts.
  • the hydrophilic solubilizing agent used in the present invention is not particularly limited as long as it contains (i) a surfactant or (mouth) a hydrophilic solvent and a surfactant, and those which can be orally administered are acceptable. preferable.
  • surfactant examples include polyoxyethylene hardened castor oils such as HCO10, HCO40, HCO50, HCO60, Cremophor RH40, polyoxyl35 hardened castor oil, and polyoxyl40 hydrogenated hardened castor oil.
  • Such Hardened castor oils such as Tween 40, Tween 60, Tween 65, Tween 80 and other polysorbates such as Labrasol®, Gelucire® 44Z14, Gelucire® 50 Polyethylene glycol 1500 fatty acid tridalicerides such as / 13, etc.
  • Polyethylene glycol fatty acid triglycerides such as polyoxyethylene hydroxystearate (SolutolHS15 (registered trademark)), etc.
  • Polyoxyethylene hydroxy fatty acid esters such as Imwiter (registered) (Trademark) 191, 308, 380, 742, glycerin fatty acid esters such as glycerin palmitostearate, and the like.
  • Fatty acids are preferably fatty acids having 1 to 50 carbon atoms.
  • vitamin E polyethylene glycol esters such as vitamin E succinate polyethylene glycol 1000 ester (Tocophersolan (registered trademark)
  • fatty acids such as stearic acid, lauric acid, palmitic acid, and oleic acid, and salts thereof. Poloxamers, sodium lauryl sulfate and the like are also preferred.
  • Examples of the surfactant used in the present invention include various polyoxyethylene hydrogenated castor oils, sodium lauryl sulfate, Gelucire44 / 14, vitamin E succinate polyethylene glycol 1,000 000 ester, polyoxyethylene hydroxystearate ester, and Imwiter 742. preferable.
  • As the surfactant those capable of solubilizing a poorly water-soluble drug in water by forming micelles with a hydrophilic solvent are preferable.
  • Examples of the hydrophilic solvent include various polyethylene glycols such as PEG400, PEG600, PEG1000, PEG 1500, PEG 1540.
  • Dimethyl sulfoxide, dimethylacetamide, dimethylformaldehyde, diethylene glycol ether and the like are preferable, and among them, various polyethylene glycols, propylene glycol and diethylene glycol ether are more preferable.
  • the hydrophilic solvent is not used alone but in combination with a surfactant. For example, even if only polyethylene glycol is used as the hydrophilic solubilizer, the intended purpose cannot be achieved.
  • the hydrophilic solubilizer may further contain a compound that gives a counter ion to the poorly water-soluble compound, if desired.
  • a compound that gives a counter ion any compound that gives a cation to an acidic drug may be used.
  • medalmine, diethanolamine, benzathine, and alkali metals (sodium, potassium, etc.), which are organic cations, may be used.
  • alkali metals sodium, potassium, etc.
  • hydroxides of alkaline earth metals magnesium, calcium, etc.
  • sodium hydroxide and potassium hydroxide are more preferable.
  • the basic drug may be any compound that gives an anion, such as hydrochloric acid, sulfuric acid, acetic acid, bromic acid, citric acid, maleic acid, tartaric acid, methanesulfonic acid, and phosphoric acid. preferable.
  • hydrochloric acid is more preferred.
  • amphoteric drug all of the aforementioned compounds are preferable, and particularly, sodium hydroxide, potassium hydroxide, and hydrochloric acid are more preferable. These are preferably used in the form of an aqueous solution.
  • the amount of the compound that gives a counter ion to the poorly water-soluble compound is preferably 0.2 to 1.2 times the molar amount of the poorly water-soluble drug. In particular, it is more preferably from 0.5 to equimolar.
  • hydrophilic solubilizer As a preferred example of the hydrophilic solubilizer according to the present invention,
  • Vitamin succinate E polyethylene glycol ester
  • Vitamin E succinate Ethylene glycol ester and (mouth) Polyethylene glycol or propylene glycol and (c) a mixture of sodium hydroxide, potassium hydroxide or hydrochloric acid
  • sodium hydroxide, potassium hydroxide and hydrochloric acid are used as an aqueous solution having an appropriate concentration.
  • the quality preservative used in the present invention is not limited as long as it contributes to the chemical or physical stability of the hard capsule filled with the contents containing the hydrophilic solubilized poorly water-soluble drug. May be. Specifically, a hard capsule filled with a poorly water-soluble drug, a solubilizing agent, and a quality preservative is subjected to an accelerated test in which it is stored at 40 ° C for 6 months, and as a result, appearance damage (for example, It is preferable that substantially no deterioration in the dissolution of the drug from the capsule is observed, such as softening, dissolving, leaking, cracking and deformation). Such a hard capsule preparation of the present invention is excellent in storage stability.
  • Examples of the quality maintaining agent used in the present invention include purified water, a thickener, and a high melting point additive.
  • Examples of the thickener include substances that make the kinematic viscosity of the content filled in the hard capsule about 100 to 2000 (mpas). More specifically, for example, a cell mouth-based system Preferred are polymers or polyvinylpyrrolidone, polyalginic acid, polyacrylic acid and the like. Alternatively, a liquid obtained by dissolving and dispersing the above substance in purified water or a polyhydric alcohol or a mixed solution thereof, or a light caustic anhydride or a polyalginic acid may be used.
  • the high melting point additive any substance can be used as long as it is solid at around room temperature and has a high melting point.
  • the melting point of the content is adjusted to about 30 to 80 a C. No. More specifically, for example, higher fatty alcohols, glycerin long-chain fatty acid esters, high-molecular-weight polyethylene glycols (100, 150, '400, 0600, 200,000) 0), polyethylene glycol 1500 fatty acid esters or vitamin succinate E polyethylene glycol 100 ester.
  • the quality preserving agent used in the present invention (a) purified water, (b) A cellulose-based polymer or polyvinylpyrrolidone (K 25, ⁇ 30, etc.), or a solution obtained by dissolving or dispersing the above substance in purified water or a polyhydric alcohol or a mixture thereof; (c) light caffeic anhydride; ) Higher fatty alcohols or (e) dali serine long chain fatty acid esters.
  • the purified water may be distilled water or physiological saline, and is preferably purified water or distilled water.
  • a solvent in which a cellulosic polymer additive or polyvinylpyrrolidone is dissolved or dispersed in purified water or a polyhydric alcohol or a mixture thereof is used as a solvent, such a solvent may also serve as a quality preservative. Therefore, it is not necessary to add a quality preservative.
  • Examples of the cellulosic polymer include hydroxypropyl cellulose, hydroxypropylmethylcellulose, and the like.
  • Examples of the polyhydric alcohol include low-molecular-weight glycols such as ethylene glycols (ethylene glycol, diethylene glycol, triethylene glycol), glycerin, propylene glycol, 1,3-butylene glycol; and polyethylene glycol.
  • ethylene glycols ethylene glycol, diethylene glycol, triethylene glycol
  • glycerin glycerin
  • propylene glycol 1,3-butylene glycol
  • polyethylene glycol polyethylene glycol
  • high molecular weight glycols having a molecular weight of about 200 to about 6,000, such as polypropylene glycol may be mentioned, and polyethylene glycol 400 or propylene glycol is more preferable.
  • the higher fatty alcohol examples include fatty alcohols having 16 to 22 carbon atoms, such as cetyl alcohol, stearyl alcohol and cetostearyl alcohol, and among them, cetostearyl alcohol is preferable.
  • the glycerin long-chain fatty acid ester refers to an ester of a long-chain fatty acid and glycerin or polyglycerin and a derivative thereof, and may be any of a monoester, a ester, a triester or a polyester.
  • esters of long-chain fatty acids and glycerin (glycerin long-chain fatty acid esters in a narrow sense), glycerin Long-chain fatty acid esters of acetic acid, glyceric acid, long-chain fatty acid esters of glycerin, glycerin lactic acid, long-chain fatty acid esters of glycerin, glycerin diacetyl tartrate, long-chain fatty acid esters of polyglycerin, and polyglycerin condensed lysylate.
  • the long-chain fatty acids include saturated or unsaturated fatty acids having 12 to 40, preferably 12 to 22 carbon atoms.
  • fatty acid for example, stearic acid, palmitostearic acid, oleic acid, lauric acid, linoleic acid, behenic acid and the like are preferable, and palmitostearic acid is more preferable.
  • the quality preservative used in the present invention is (a) purified water, (b) a cellulosic polymer additive, polybierpyrrolidone, or the like, or purified water, polyethylene glycol 400 or propylene glycol or One or more selected from the group consisting of a solution dissolved and dispersed in a mixture thereof, (c) light gay anhydride, (d) cetostearyl alcohol, and (e) glyceryl palmitostearate.
  • One additive may have both a role as a hydrophilic solubilizer and a role as a quality preservative, for example, higher fatty alcohols or dalyserin fatty acid esters. Purified water is most preferred as the quality preservative used in the present invention.
  • the content of the poorly water-soluble drug in the preparation is about 0.1% to about 50% by weight, and about 1% to about 30% by weight is more preferable. preferable.
  • the content of the hydrophilic solubilizer in the preparation is preferably from about 20% to about 99.8% by weight, more preferably from about 50% to about 90% by weight.
  • the content of the hydrophilic solvent in the preparation is preferably about 0.1% by weight to about 20% by weight, more preferably about 1% by weight to about 10% by weight.
  • the content of the quality preservative in the preparation is preferably from about 0.1% to about 30% by weight, more preferably from about 1% to about 20% by weight.
  • a capsule material constituting the hard capsule according to the present invention
  • a known material may be used, but a material that is acceptable for oral administration is particularly preferable.
  • examples include agar, alginate, starch, xanthan or dextran, which are naturally occurring polysaccharides, and gelatin or zein, which is a protein.
  • Chemically treated products include hydroxystarch, pullulan, hydroxypropylcellulose, hydroxypropylmethylcellulose, polyvinyl alcohol or derivatives thereof, polyacryl derivatives, polyvinylpyrrolidone or derivatives thereof, and polyethylene glycol.
  • the hard capsules according to the present invention are preferably gelatin hard capsules, hydroxypropylmethylcellulose hard capsules or pullulan hard capsules, and more preferably hydroxypropylmethylcellulose hard capsules or pullulan hard capsules.
  • the hard capsule used in the present invention can be easily produced according to a known method. For example, a method in which a molding pin is immersed in an aqueous solution (die) in which the above-mentioned capsule material, and if desired, a gelling agent and, if desired, a gelling aid is dissolved, is lifted, is gelled, and is dried. With this, a hard capsule can be obtained.
  • the hard capsule obtained as described above is filled with a poorly water-soluble drug, a hydrophilic solubilizer, and a quality preservative, preferably after uniformly mixing, dissolving or dispersing them, thereby filling the capsule.
  • the hard capsule of the invention can be obtained.
  • other additives may be filled in the capsule, as long as the object of the present invention is not adversely affected.
  • additives that are commonly used for the purpose according to the use of the hard capsule preparation of the present invention can be used.
  • compositions For example, food colors, opacifiers, viscosity modifiers Agents, gelling agents, gelling auxiliaries or excipients (eg, lactose, glucose, shonan, mannitol, etc.).
  • gelling agents e.g, lactose, glucose, shonan, mannitol, etc.
  • excipients eg, lactose, glucose, shonan, mannitol, etc.
  • the method of filling the contents may be performed according to a conventional method.
  • the above-mentioned eighteen capsule (composed of a pair of a body and a cap) is set in a drug filling machine, and after separating the body and the cap, the body is filled with a certain amount of contents and the cap is connected.
  • a so-called band seal microspray sealing is preferably applied to the joint between the cap and the body using the same components as the capsule material.
  • the cap is closed and the joint is quickly fused to perform sealing.
  • a hydrophilic solubilizing agent is contained, if there is only an additive that maintains the quality of hard capsules, the contents containing a poorly water-soluble drug with improved absorbability upon oral administration can be prepared.
  • solid preparations for oral administration can be made.
  • the content to be filled into the hard capsule may be in any form such as liquid, semi-solid or solid (for example, powder, granule or tablet), but from the viewpoint of improving absorbability during oral administration. It is preferable that the compound has a liquid or semi-solid form.
  • Liquid and semi-solid contents can be obtained according to known methods.
  • the liquid content can be obtained by dissolving or dispersing a poorly water-soluble drug, a hydrophilic solubilizer, an emulsifier, a quality preservative, and other additives as required in a suitable solvent.
  • the solvent can be appropriately selected according to the use of the hard capsule preparation of the present invention. If a thickener is used as a quality preserving agent, a thickener and a thickener auxiliary agent are used at this time. You may use simultaneously.
  • any solid cellulose-based polymer additive a carrier capable of dissolving and dispersing polyvinylpyrrolidone, light caffeic anhydride, polyalginic acid, polyacrylic acid, etc. may be used. Alcohol, glycerin, etc. or their mixture Are preferred.
  • a high melting point additive is used as a quality preservative, a semi-solid content can be prepared.
  • the high melting point hydrophilic solubilizer of the present invention can also be used.
  • higher fatty alcohols, glycerin long-chain fatty acid esters, high molecular weight polyethylene glycols such as PEG1000, PEG 1500, PEG4000, PEG6000, PEG20000, polyethylene glycol 1500 fatty acid esters, or vitamin E succinate E polyethylene glycol 1000 ester Is preferred.
  • higher fatty alcohols, glycerin long-chain fatty acid esters, high molecular weight polyethylene glycols such as PEG1000, PEG 1500, PEG 4000, PEG 6000, and PEG 20000, polyethylene glycol 1500 fatty acid esters, and vitamin E succinate E polyethylene glycol 1000 ester are more preferable.
  • the hard capsule preparation of the present invention is applicable to drugs or foods, drugs for animals or plants, fertilizers, feeds, and the like.
  • it can be applied not only to orally administered drugs, but also to parenteral drugs such as inhalants and external preparations such as suppositories.
  • parenteral drugs such as inhalants
  • external preparations such as suppositories.
  • quasi-drug for the purpose of disinfecting and cleaning dentures, eyeglasses, contact lenses, and the like.
  • Example 5 5 parts of HS 15 and 1 part of PG and 1 part of purified water and high-grade fat melted at about 40 ° C Three parts of fatty alcohol were mixed well, and the resulting mixture was filled into the first size HGC, HPMC or HPC with a commercially available disposable lm 1 syringe in an amount of about 0.3 ml each to obtain hard capsules. .
  • Example 5 5 parts of HS 15 and 1 part of PG and 1 part of purified water and high-grade fat melted at about 40 ° C Three parts of fatty alcohol were mixed well, and the resulting mixture was filled into the first size HGC, HPMC or HPC with a commercially available disposable lm 1 syringe in an amount of about 0.3 ml each to obtain hard capsules. .
  • Example 5 5 parts of HS 15 and 1 part of PG and 1 part of purified water and high-grade fat melted at about 40 ° C Three parts of fatty alcohol were mixed well, and the resulting mixture was filled into the first
  • Production Examples 1 to 8 are placed in a test tube with the body part down so that the internal solution does not leak from the joint between the cap and the body, and the opening of the test tube is sealed. They were stored for 6 months in a constant temperature room at 40 ° C, an accelerated test condition equivalent to one year, and changes in appearance (dissolution, cracking, leakage, deformation, etc.) were observed. The results are shown in the table below. In the table, ⁇ indicates that there is no change in appearance, and X indicates that softening, cracking, leakage, and deformation occur. Table 1
  • the dissolution rate from the three kinds of capsules of Examples 1 to 6 containing the quality preservative was the same as that of the non-preserved product, and the dissolution rate of acetaminophen after 45 minutes was 85% or more. This shows that there was no adverse effect of various hydrophilic solubilizers on quality. Toes In addition, it was found that purified water, PVP, higher fatty alcohol, glycerin medium-chain fatty acid ester, and light acid anhydride were effective as a quality preservative for forcepsell materials.
  • danazol was dissolved by mixing lg (10% by weight) of danazol, 7 g of TPGS, 0.7 g of PEG and 0.6 g of sodium lauryl sulfate under heating at about 80 ° C. . After dissolution, add 0.7 g of purified water and mix well.Fill this solution with 0.3 g of HGC, HPM C or HP C capsule of No. 1 size using a commercially available disposable lm 1 syringe. A danazol capsule containing about 30 mg per capsule was prepared.
  • Hard capsules were prepared with the same hydrophilic solubilizer composition as in Example 2 as follows.
  • 0.05 g of polyvinylpyrrolidone K25 was previously mixed well with 0.3 g of PEG400 and 0.05 g of purified water while heating at about 80 ° C., and dissolved.
  • 0.7 g of TPGS was added to this mixed solution, mixed well and dissolved.
  • 0.2 g (15.4% by weight) of cyclosporine was added, mixed well at about 80 ° C. and dissolved.
  • This drug solution was filled into HPMC or HPC capsules of No. 1 size by about 0.3 ml each using a commercially available disposable lml syringe to prepare cyclosporine capsules containing about 45 mg per capsule.
  • Hard capsules were prepared with the same hydrophilic solubilizing agent composition as in Example 3 as follows. That is, evening crolimus 0.2 g (10% by weight) and TPGS 1.4 g And PG were mixed well with 0.2 g under heating at about 80 ° C to dissolve chlorimus in the evening. After dissolution, add 0.05 g of purified water and mix well.Fill this solution with a commercially available disposable lm l syringe into each No. 1 size HGC or HPC capsule in approximately 0.3 m1. A tact-mouth limus capsule containing about 30 mg per capsule was prepared.
  • Example 10 Example 10
  • Hard capsules were prepared with the same hydrophilic solubilizer composition as in Example 4 as follows. That is, 2 g (17% by weight) of probucol, 7 g of HS 15, 1 g of PG, and cetostearyl alcohol were mixed well under heating at about 80 ° C to dissolve probucol. After dissolution, add 0.5 g of purified water and mix well.Fill this solution with a commercially available disposable lm 1 syringe into each No. 1 size HGC or HPC capsule in approx.0.3 ml each, 1 capsule A probucol capsule containing about 5 Omg per was prepared.
  • Hard capsules were prepared with the same hydrophilic solubilizing agent composition as in Example 5 as follows. In other words, 0.3 g (10% by weight) of evening moxifen, 1.4 g of Gelucire44 / 14 melted at 60 ° C, 0.6 g of Labrasol, and 0.2 g of dimethylene glycol were dissolved. g and 0.5 g of glycerin palmitostearate, a long-chain fatty acid ester of glycerin, were mixed well at about 60 and dissolved. After dissolution, add 0.05 g of purified water and mix well.Fill this drug solution with a commercially available disposable lm 1 syringe into each of the first size HGC or HPC capsules in approx.
  • Example 1 2 Using the same hydrophilic solubilizing agent composition as in Example 6, 81 capsules were prepared as follows. In other words, 15 g of Imwiter 742 melted at about 60 ° C and 2 g of polyoxyethylene hydrogenated castor oil (HCO) 60 are mixed well under about 60, and 1 g of albendazole (5 wt% ) Was added and dissolved. In addition, 1 part of light anhydrous silicic acid was added and mixed well. Fill the obtained mixture with each of the No. 1 size HGC, HPMC, or HPC using a commercially available disposable lm 1 syringe with about 0.3 ml each to prepare an albendazole capsule containing about 15 mg per capsule. did.
  • Example 13 Example 13
  • Example 14 Eighteen capsules were prepared with the same hydrophilic solubilizer composition as in Example 1 as follows. In other words, 7.13 g of TPGS dissolved in 2.5 g (22% by weight) of albendazole at about 60 ° C, lg of PEG400, and 0.87 g of 12N hydrochloric acid aqueous solution at about 60 ° C Mix well with C and dissolve. The obtained liquid mixture was filled into HGC, HPMC or HPC of No. 1 size by about 0.3 ml each with a commercially available disposable lml syringe to prepare an albendazole capsule containing about 66 mg per capsule.
  • Example 14 Example 14
  • a hard capsule was prepared as follows. In other words, 3 g (25% by weight) of domperidone and 7.35 g of HS 15 melted at about 40 ° C, 1 g of PG, and 0.65 g of 12N hydrochloric acid aqueous solution at about 60 ° C Mix well and dissolve the obtained mixture into each of the 1st size HGC, HPMC or HPC with a commercially available disposable 1 m 1 syringe, filling about 0.3 ml each, and a capsule containing about 75 nag per capsule. Don capsules were prepared.
  • Example 15 Example 15
  • Example 16 Eighteen capsules were prepared with the same hydrophilic solubilizer composition as in Example 4 as follows. In other words, 4 g (29% by weight) of Todari Yuzon and 7.2 g of HS 15 melted at about 40 ° C, 1 g of PG, and 1.8 g of 4N potassium hydroxide aqueous solution were added to about 60 g. Mix well at ° C and dissolve. The resulting mixture is filled into each No. 1 size HGC, HPMC or HPC with a commercially available disposable lm 1 syringe in about 0.31 ml each, containing about 9 Omg per capsule A todary evening capsule was prepared.
  • Example 16 Example 16
  • Example 17 Using the same hydrophilic solubilizing agent composition as in Example 1, 81 capsules were prepared as follows. That is, 3.5 g (25% by weight) of pranlukast, 8 g of TPGS melted at about 60 ° C, 1 g of PEG400, and 1.5 g of 4N aqueous sodium hydroxide solution at about 60 ° C Mix well with C. The resulting mixture is filled into each No. 1 size HG C, HPMC or HPC using a commercially available disposable lml syringe in an amount of about 0.3 ml, and pranluca containing about 75 mg per capsule A strike capsule was prepared.
  • Example 17 Example 17
  • ibuprofen 5 g (50% by weight) of ibuprofen, 3 g of HS 15 and 1 g of PG are mixed well, and then 1 g of 12N aqueous sodium hydroxide solution is added. Dissolved. The resulting mixed solution was filled into the first size HGC, HPMC, and HPC with a commercially available disposable lm 1 syringe in an amount of 0.3 ml to prepare an ibuprofen capsule containing about 15 Omg per capsule.
  • the capsule fillings of Examples 7 to 17 were all prepared using artificial gastric juice (pH 1.2) and artificial intestinal juice (pH 6. 8), and the poorly water-soluble drug did not precipitate in the solution for 2 hours. It can be seen that the absorption of the poorly water-soluble drug into the living body is improved.
  • the hard capsule of the present invention may contain a hydrophilic solubilizing agent for improving the solubility of a poorly water-soluble drug in water, for example, the appearance change such as softening, dissolution, leakage, cracking and deformation, or the drug Substantially no qualitative change such as deterioration of the dissolution property of the compound is observed.
  • a hydrophilic solubilizing agent for improving the solubility of a poorly water-soluble drug in water, for example, the appearance change such as softening, dissolution, leakage, cracking and deformation, or the drug Substantially no qualitative change such as deterioration of the dissolution property of the compound is observed.
  • the hard force presser of the present invention does not substantially limit the viscosity of the contents, and can also fill contents having a relatively high viscosity. Further, the hard capsule preparation of the present invention is hardly affected by the humidity and temperature of the environment, and is easy to distribute and handle.

Abstract

La présente invention a trait à une capsule dure caractérisée en ce qu'elle contient un médicament peu hydrosoluble, un agent de solubilisation hydrophile et un agent d'amélioration de la qualité dans laquelle l'absorbabilité du médicament peu hydrosoluble est améliorée par l'amélioration de la dissolution du médicament peu hydrosoluble et qui présente d'excellentes qualités dans le stockage à long terme.
PCT/JP2004/001751 2003-02-18 2004-02-17 Capsule dure de medicament peu hydrosoluble WO2004073692A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2005502715A JPWO2004073692A1 (ja) 2003-02-18 2004-02-17 難水溶性薬物のハードカプセル剤

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2003-39562 2003-02-18
JP2003039562 2003-02-18

Publications (1)

Publication Number Publication Date
WO2004073692A1 true WO2004073692A1 (fr) 2004-09-02

Family

ID=32905175

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2004/001751 WO2004073692A1 (fr) 2003-02-18 2004-02-17 Capsule dure de medicament peu hydrosoluble

Country Status (2)

Country Link
JP (1) JPWO2004073692A1 (fr)
WO (1) WO2004073692A1 (fr)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006082842A1 (fr) * 2005-02-03 2006-08-10 Qualicaps Co., Ltd. Gélule dure de solubilité améliorée
WO2008099615A1 (fr) 2007-02-16 2008-08-21 Aska Pharmaceutical Co., Ltd. Composition pharmaceutique contenant une suspension à base d'huile en fines particules
JP2009506027A (ja) * 2005-08-26 2009-02-12 エスケー ケミカルズ カンパニー リミテッド 初期溶解率が改善されたプランルカスト固体分散体の薬剤学的組成物およびその製造方法
JP2012062248A (ja) * 2010-09-14 2012-03-29 Taisho Pharmaceutical Co Ltd イプリフラボン可溶化組成物
JP2019026643A (ja) * 2017-07-31 2019-02-21 東洋製薬化成株式会社 バンコマイシン懸濁液充填カプセル製剤

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6578459B1 (ja) * 2019-02-28 2019-09-18 アピ株式会社 ハードカプセル及びその製造方法

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5665820A (en) * 1979-11-02 1981-06-03 Eisai Co Ltd Hard capsule with high content of tocopherol nicotinate
JPS57149219A (en) * 1981-03-12 1982-09-14 Eisai Co Ltd Hard capsule preparation containing tocopherol nicotinate in high concentration
JPH08512303A (ja) * 1993-07-08 1996-12-24 チバ−カイギー アクチェンゲゼルシャフト 難溶性活性物質のための医薬製剤
JP2000237284A (ja) * 1999-02-17 2000-09-05 Shionogi Qualicaps Kk 硬質カプセル製剤
JP2001031565A (ja) * 1999-07-19 2001-02-06 Nisshin Flour Milling Co Ltd ロキソプロフェンナトリウム含有カプセル製剤
WO2001022942A1 (fr) * 1999-09-27 2001-04-05 American Cyanamid Company Formulation de transporteurs pharmaceutiques
JP2001302544A (ja) * 1999-12-10 2001-10-31 Takeda Chem Ind Ltd 経口用医薬組成物
JP2003500368A (ja) * 1999-05-24 2003-01-07 ソーナス ファーマシューティカルス，インコーポレイテッド 溶解度が不十分な薬剤のためのエマルジョンビヒクル

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5665820A (en) * 1979-11-02 1981-06-03 Eisai Co Ltd Hard capsule with high content of tocopherol nicotinate
JPS57149219A (en) * 1981-03-12 1982-09-14 Eisai Co Ltd Hard capsule preparation containing tocopherol nicotinate in high concentration
JPH08512303A (ja) * 1993-07-08 1996-12-24 チバ−カイギー アクチェンゲゼルシャフト 難溶性活性物質のための医薬製剤
JPH08512301A (ja) * 1993-07-08 1996-12-24 サンド・リミテッド 難溶性活性物質のための医薬組成物
JP2000237284A (ja) * 1999-02-17 2000-09-05 Shionogi Qualicaps Kk 硬質カプセル製剤
JP2003500368A (ja) * 1999-05-24 2003-01-07 ソーナス ファーマシューティカルス，インコーポレイテッド 溶解度が不十分な薬剤のためのエマルジョンビヒクル
JP2001031565A (ja) * 1999-07-19 2001-02-06 Nisshin Flour Milling Co Ltd ロキソプロフェンナトリウム含有カプセル製剤
WO2001022942A1 (fr) * 1999-09-27 2001-04-05 American Cyanamid Company Formulation de transporteurs pharmaceutiques
JP2001302544A (ja) * 1999-12-10 2001-10-31 Takeda Chem Ind Ltd 経口用医薬組成物

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006082842A1 (fr) * 2005-02-03 2006-08-10 Qualicaps Co., Ltd. Gélule dure de solubilité améliorée
JP2009506027A (ja) * 2005-08-26 2009-02-12 エスケー ケミカルズ カンパニー リミテッド 初期溶解率が改善されたプランルカスト固体分散体の薬剤学的組成物およびその製造方法
WO2008099615A1 (fr) 2007-02-16 2008-08-21 Aska Pharmaceutical Co., Ltd. Composition pharmaceutique contenant une suspension à base d'huile en fines particules
US8309138B2 (en) 2007-02-16 2012-11-13 Aska Pharmaceutical Co., Ltd. Pharmaceutical composition comprising microparticle oily suspension
JP2012062248A (ja) * 2010-09-14 2012-03-29 Taisho Pharmaceutical Co Ltd イプリフラボン可溶化組成物
JP2019026643A (ja) * 2017-07-31 2019-02-21 東洋製薬化成株式会社 バンコマイシン懸濁液充填カプセル製剤
JP7118412B2 (ja) 2017-07-31 2022-08-16 東洋製薬化成株式会社 バンコマイシン懸濁液充填カプセル製剤

Also Published As

Publication number Publication date
JPWO2004073692A1 (ja) 2006-06-01

Similar Documents

Publication Publication Date Title
JP4523799B2 (ja) 医薬組成物
JP2015155433A (ja) ペプチドの組成物及びその調製方法
EP3766480A1 (fr) Comprimé à désintégration orale contenant des particules lipidiques solides, et son procédé de préparation et d'utilisation
JPH11510506A (ja) 結腸からの極性薬剤の摂取を増強するための組成物
WO2011151086A1 (fr) Formes posologiques orales de la bendamustine et leur utilisation therapeutique
CN1903228A (zh) 灵芝孢子油自乳化制剂及其制备方法
KR20070119700A (ko) 페노피브레이트 및 계면 활성제 혼합물을 함유하는 제제
CZ286051B6 (cs) Farmaceutický prostředek a způsob jeho použití pro dasažení projímavého účinku
CN102056599A (zh) 吲哚满酮衍生物的立即释放药物剂型
WO2015022349A1 (fr) Forme pharmaceutique comprenant de l'enzalutamide
EP3332775A1 (fr) Capsule entérique
CZ306618B6 (cs) Kompozice obsahující sloučeniny modafinylu
CZ51995A3 (en) Substantially anhydrous pharmaceutical preparation for oral administration of active component
WO2004073692A1 (fr) Capsule dure de medicament peu hydrosoluble
JP2005526758A (ja) ハードシェルカプセル剤のためのイブプロフェン溶液
CN102188417A (zh) 决奈达隆药物组合物
JPWO2005065715A1 (ja) 造粒性改善方法
JP2017518980A (ja) タペンタドールを含む、改変防止即時放出カプセル製剤
JP2018123140A (ja) 活性成分（ｉ）含有組成物及びその製造方法
EP4057996A1 (fr) Compositions pharmaceutiques amorphes d'acétate d'abiratérone
US20200323985A1 (en) Formulation for oral delivery of proteins, peptides and small molecules with poor permeability
US20180177735A1 (en) Stable Pharmaceutical Composition Of Phytonadione And A Novel Process For Preparation Thereof
JP2007504190A (ja) ３−［（２−｛［４−（ヘキシルオキシカルボニルアミノ−イミノ−メチル）−フェニルアミノ］−メチル｝−１−メチル−１ｈ−ベンズイミダゾール−５−カルボニル）−ピリジン−２−イル−アミノ］−エチルプロピオネート及びそれらの塩の新規経口投与形態
CN102697764A (zh) 一种含有异硫氰酸苯乙酯的肠溶固体制剂
TWI834862B (zh) 用於經口投遞滲透性不良蛋白質、肽及小分子之調配物

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2005502715

Country of ref document: JP

122 Ep: pct application non-entry in european phase